410P Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): final analysis.
Authors
Olszanski, AGonzalez, R
Corrie, P
Pavlick, A
Middleton, M
Lorigan, Paul C
Plummer, R
Skaria, S
Herbert, C
Gore, M
Agarwala, S
Daud, A
Zhang, S
Bahamon, B
Rangachari, L
Hoberman, E
Kneissl, M
Rasco, D
Affiliation
Department of Medical Hematology/Oncology, Fox Chase Cancer Center,Issue Date
2017-09
Metadata
Show full item recordCitation
410P Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): final analysis. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx367.043Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx367.043/4108632/410PPhase-I-study-of-the-investigational-oralType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx367.043